26 Sep 2013 07:00
Omega Diagnostics Group PLC
("Omega" or the "Company")
CD4 Update
Omega (AIM:ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces the following update on its CD4 technology transfer project.
Further to the update given at the time of our final results in July, we selected a preferred manufacturing protocol to produce prototype devices to undertake a three-batch evaluation. We have reviewed the results from patient samples tested using the first reference batch and there has been more variability in the results than expected. This has generated some additional work as we refine production processes. We continue to work closely with the Burnet Institute with the aim of achieving a successful transfer of the technology and we estimate that the additional work to complete the three-batch evaluation could now take until the end of December 2013. We will reaffirm this timeline by the end of October 2013.
The Group intends to announce a trading update on 17 October 2013.
Contacts:
Omega Diagnostics Group PLC | Tel: 01259 763 030 |
Andrew Shepherd, Chief Executive | www.omegadiagnostics.com |
Kieron Harbinson, Group Finance Director | |
Jag Grewal, Group Sales and Marketing Director | |
finnCap Ltd | Tel: 020 7220 0500 |
Geoff Nash/Christopher Raggett (Corporate Finance) | |
Stephen Norcross/Mia Gardner (Corporate Broking) | |
Walbrook PR Limited | Tel: 020 7933 8780 or omega@walbrookpr.com |
Paul McManus | Mob: 07980 541 893 |
Lianne Cawthorne | Mob: 07584 391 303 |